Aurobindo Pharma Ltd (AUROPHARMA) Q1 FY27 Results Analysis: PAT Jumps 25.2%, Gross Margin Expands 160 bps
Aurobindo Pharma Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 9,150.35 Cr (+16.30% YoY) and PAT growth of +25.20% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | August 05, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 9,150.35 Cr (+16.30% YoY) |
| PAT (Q1) | Rs. 1,032.56 Cr (+25.20% YoY) |
| EBITDA margin | 20.56% (+18 bps YoY) |
| EPS (Q1) | Rs. 17.86 (+25.80% YoY) |
| Market cap | Rs. 93,830.78 Cr |
| CMP | Rs. 1,613.40 |
Quarter Snapshot
Auropharma delivered a solid Q1 with 16.3% YoY revenue growth and 25.2% PAT growth, driven by favourable forex tailwinds, Europe formulations momentum, and Pen-G turning EBITDA-positive. Gross margins expanded 160 bps YoY to 60.4%, while the recently closed Lannett acquisition and ongoing Pen-G/biosimilar ramp-up provide near-term catalysts toward the stated FY27 EBITDA margin target of >21%.
Key Investment Insights
Key Positives
- Revenue grew 16.3% YoY to Rs.9,150.35 Cr, the fastest quarterly clip in several periods
- PAT-to-owners grew 25.2% YoY to Rs.1,032.56 Cr, outpacing revenue growth
- Gross margin expanded 160 bps YoY to 60.4%, the highest in the trailing year
- EBITDA grew 17.3% YoY to Rs.1,880.96 Cr, with margin improving to 20.56% from 20.38% a year ago
- Normalized PAT (excluding exceptional items) grew 28.5% YoY to Rs.1,059.40 Cr
- Europe formulations momentum continues, having achieved €1 Bn annual revenue in FY26 (up 23.4% YoY)
- Pen-G production is generating positive EBITDA, contributing to API growth
Risk Factors
- Employee benefits expense grew 20.5% YoY (16.2% of revenue vs 15.6% a year ago), driven by annual increments and headcount additions
- Effective Tax Rate jumped to 31.88% from 28.65% QoQ, reverting to year-ago level
- Standalone revenue declined 1.71% YoY, reflecting the shift where subsidiary operations now drive group growth
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.